• NextCell Pharma reported numerically favorable 12-month results for NXTCL-T1D in children aged 7-11 with type 1 diabetes, without statistically significant benefit.
• The ProTrans-Young trial showed no statistically significant overall benefit in preserving insulin production.
• Preliminary 24-month results in patients aged 12-21 showed no clear treatment benefit; full results will follow completion of analyses.
• The adult commercialization strategy remains a single infusion within two years of diagnosis, supported by statistically significant results from an earlier trial.
• Future pediatric development will assess earlier treatment and repeated dosing to improve preservation of patients’ own insulin production.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NextCell Pharma AB published the original content used to generate this news brief via Cision (Ref. ID: 20261025:BIT:9552:0) on October 26, 2026, and is solely responsible for the information contained therein.